经导管主动脉瓣植入术的性别模式与趋势
女性TAVI比例从2013年47.6%降至2022年43.6%,围术期死亡率、血管并发症和出血风险高于男性,但长期死亡率较低(AHR 0.92)。
要点
- 女性TAVI比例十年间从47.6%降至43.6%(P < .001)。
- 女性围术期死亡率(AOR 1.20)、血管并发症(AOR 1.65)和出血(AOR 1.67)风险高于男性。
- 女性长期死亡率较低(AHR 0.92),但心衰住院、心梗、卒中和出血风险较高。
核心结论
- 在Medicare受益者中,女性接受TAVI的比例逐渐下降,围术期并发症更多,但长期生存略优于男性。
研究设计与样本
- 全国性回顾性人群队列研究,使用2013年1月1日至2022年12月31日美国Medicare按服务收费受益者TAVI出院索赔数据,中位随访2.19年(IQR 0.94-3.79)。
主要发现
- 女性TAVI比例从2013年47.6%下降至2022年43.6%(P < .001)。
- 女性围术期死亡率2.5% vs 男性2.2%(AOR 1.20,95%CI 1.14-1.26)。
- 女性血管并发症5.8% vs 3.6%(AOR 1.65,95%CI 1.60-1.71),出血10.4% vs 6.8%(AOR 1.67,95%CI 1.62-1.71)。
- 女性永久起搏器植入率16.9% vs 20.0%(AOR 0.81,95%CI 0.79-0.82)。
- 女性长期全因死亡率较低(AHR 0.92,95%CI 0.91-0.93),但心衰住院、急性心梗、卒中和出血风险较高。
临床怎么用
- 临床中应关注女性TAVI患者围术期血管并发症和出血风险的管理。
- 女性TAVI比例下降的趋势需进一步研究以优化性别特异性策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sex-related disparities affect diagnosis, referral, and prognosis of aortic valvular diseases. Contemporary US data on transcatheter aortic valve implantation (TAVI) by sex are limited. OBJECTIVE: To characterize 10-year trends in TAVI use, periprocedural complications, and long-term outcomes among Medicare beneficiaries, stratified by sex. DESIGN, SETTING, AND PARTICIPANTS: This nationwide, retrospective, population-based cohort study used US Medicare claims data from fee-for-service beneficiaries discharged after TAVI from January 1, 2013, to December 31, 2022. The median follow-up time was 2.19 (IQR, 0.94-3.79) years. Exclusions included patients who had concomitant valve surgery, infective endocarditis, valve-in-valve TAVI, transapical TAVI, TAVI for pure aortic insufficiency, or later conversion to Medicare Advantage. Analyses were conducted between October 1, 2024, and April 1, 2025. EXPOSURE: TAVI. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality. Secondary outcomes included periprocedural mortality, vascular complications, acute kidney injury, major or life-threatening bleeding, stroke, acute myocardial infarction (AMI), permanent pacemaker implantation (PPI), and hospitalization for heart failure (HF). Adjusted odds ratios (AORs) and hazard ratios (AHRs) with 95% CIs were estimated. RESULTS: The study included 314 123 patients (141 233 women [45.0%] and 172 890 men [55.0%]). Women were older than men (mean [SD] age, female: 80.3 [7.8] years; male: 79.4 [7.7] years; standardized mean difference, 12%). The proportion of female patients who underwent TAVI declined from 47.6% in 2013 to 43.6% in 2022 (P < .001). Compared with men, women had higher periprocedural mortality (2.5% vs 2.2%; AOR, 1.20 [95% CI, 1.14-1.26]), vascular complications (5.8% vs 3.6%; AOR, 1.65 [95% CI, 1.60-1.71]), and bleeding (10.4% vs 6.8%; AOR, 1.67 [95% CI, 1.62-1.71]) but less PPI (16.9% vs 20.0%; AOR, 0.81 [95% CI, 0.79-0.82]). Long-term mortality was lower in female patients (AHR, 0.92; 95% CI, 0.91-0.93), although their risks of HF hospitalization, AMI, stroke, and bleeding were higher. CONCLUSIONS AND RELEVANCE: Among Medicare beneficiaries, women constituted a progressively declining proportion of patients treated with TAVI, experienced more periprocedural complications, and demonstrated modestly better long-term survival compared with men. Further work is needed to understand factors influencing these trends and to refine sex-specific strategies for optimal outcomes.
引用
- Nicolas J, Gelijns AC, Moskowitz AJ, et al. Sex-Based Patterns and Trends in Transcatheter Aortic Valve Implantation. JAMA Cardiol. 2026. PMID: 42090130. doi:10.1001/jamacardio.2026.0941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。